Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709592 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00709592: Completed Phase 2 study, sponsored by Virginia Commonwealth University.
NCT00709592 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709592, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
Primary Outcome
A positive test result will indicate immune reconstitution, while a negative test results will indicate lack of immune reconstitution. Participants not done (ND) will be counted with the negative (Neg).
Interventions
- RADIATION Total-Body Irradiation
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- BIOLOGICAL Thymoglobulin
- PROCEDURE Allogeneic PBSCT or BMT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-07-21 |
| Est. Completion | 2017-06-28 |
| Phase | Phase 2 |
What the finished NCT00709592 record still lists
NCT00709592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Total-Body Irradiation is the first listed.
NCT00709592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00709592 about?
NCT00709592 is a clinical study titled "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT". One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
What is the current status of trial NCT00709592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2008-07-21. Estimated completion is 2017-06-28.
What interventions are being tested in trial NCT00709592?
The interventions under investigation include: Total-Body Irradiation (RADIATION), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Thymoglobulin (BIOLOGICAL), Allogeneic PBSCT or BMT (PROCEDURE).
Who is sponsoring clinical trial NCT00709592?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00709592's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI